RSV stands for Respiratory Syncytial Virus, a common virus that can cause respiratory infections ranging from mild to severe.

On April 5, 2024, the first in human clinical trial of NXP-800 was reported in 2024 AACR.

Marinus Pharmaceuticals, Inc. has declared that the independent Data Monitoring Committee has advised proceeding with the crucial Phase 3 RAISE trial.

The EU's pharmaceutical regulatory system is a complex, multi-layered network with various agencies working together to safeguard the safety, efficacy, and quality of medicines in the European Economic Area.

The EU's pharmaceutical regulatory system is a complex, multi-layered network with various agencies working together to safeguard the safety, efficacy, and quality of medicines in the European Economic Area.

April 18th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

NiKang Therapeutics has administered the initial dose to a patient in its Phase 1/1b trial of NKT3447, an oral drug targeting CDK2 that decreases Cyclin E levels.

On April 5, 2024, the latest clinical findings of IMM27M were unveiled at the 2024 AACR, demonstrating its potential effect and setting the stage for subsequent investigations.

Both the GMP (Good Manufacturing Practice) systems in China and the United States aim to ensure quality control and safety in pharmaceutical production.

On April 5, 2024, the first-in-human phase I study of CTX-712 in patients with advanced, relapsed or refractory malignant tumors (CTX-712-CL-01 study) was reported in 2024 AACR.

On April 12, 2024, Arvinas announced that it has entered into an exclusive strategic license agreement with Novartis to collaborate on the development of Arvinas' second-generation androgen receptor (AR) degrader, ARV-766.

On April 7, 2024, the latest clinical data of Cadonilimab (the PD-1/CTLA-4 bispecific antibody) plus chemo were reported in 2024 AACR.